Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sheena Tam is active.

Publication


Featured researches published by Sheena Tam.


American Journal of Respiratory Cell and Molecular Biology | 2011

Acute lung injury induces cardiovascular dysfunction: Effects of IL-6 and budesonide/formoterol

Koichi Suda; Masashi Tsuruta; Jihyoun Eom; Chris Or; Tammy Mui; Jen Erh Jaw; Yuexin Li; Ni Bai; Joseph Kim; Julie Man; David A. Ngan; Jee Lee; Srøen Hansen; Seung Won Lee; Sheena Tam; S. Paul Man; Stephan F. van Eeden; Don D. Sin

Acute lung injury (ALI) is associated with systemic inflammation and cardiovascular dysfunction. IL-6 is a biomarker of this systemic response and a predictor of cardiovascular events, but its possible causal role is uncertain. Inhaled corticosteroids and long-acting β2 agonists (ICS/LABA) down-regulate the systemic expression of IL-6, but whether they can ameliorate the cardiovascular dysfunction related to ALI is uncertain. We sought to determine whether IL-6 contributes to the cardiovascular dysfunction related to ALI, and whether budesonide/formoterol ameliorates this process. Wild-type mice were pretreated for 3 hours with intratracheal budesonide, formoterol, or both, before LPS was sprayed into their tracheas. IL-6-deficient mice were similarly exposed to LPS. Four hours later, bronchoalveolar lavage fluid (BALF) and serum were collected, and endothelial and cardiac functions were measured, using wire myography of the aortic tissue and echocardiography, respectively. LPS significantly impaired vasodilatory responses to acetylcholine (P < 0.001) and cardiac output (P = 0.002) in wild-type but not IL-6-deficient mice. Intratracheal instillations of exogenous IL-6 into IL-6-deficient mice restored these impairments (vasodilatory responses to acetylcholine, P = 0.005; cardiac output, P = 0.025). Pretreatment with the combination of budesonide and formoterol, but not either alone, ameliorated the vasodilatory responses to acetylcholine (P = 0.018) and cardiac output (P < 0.001). These drugs also attenuated the rise in the systemic expression of IL-6 (P < 0.05) related to LPS. IL-6 contributes to the cardiovascular dysfunction related to LPS, and pretreatment with budesonide/formoterol reduces the systemic expression of IL-6 and improves cardiovascular dysfunction. ICS/LABA may reduce acute cardiovascular events related to ALI.


PLOS ONE | 2015

Absolute Leukocyte Telomere Length in HIV-Infected and Uninfected Individuals: Evidence of Accelerated Cell Senescence in HIV-Associated Chronic Obstructive Pulmonary Disease

Joseph Liu; Janice M. Leung; David A. Ngan; Negar F. Nashta; Silvia Guillemi; Marianne Harris; Viviane D. Lima; Soo-Jung Um; Yuexin Li; Sheena Tam; Tawimas Shaipanich; Rekha Raju; Cameron Hague; Jonathon Leipsic; Jean Bourbeau; Wan C. Tan; P. Richard Harrigan; Don D. Sin; Julio S. G. Montaner; S. F. Paul Man

Combination antiretroviral therapy (cART) has extended the longevity of human immunodeficiency virus (HIV)-infected individuals. However, this has resulted in greater awareness of age-associated diseases such as chronic obstructive pulmonary disease (COPD). Accelerated cellular senescence may be responsible, but its magnitude as measured by leukocyte telomere length is unknown and its relationship to HIV-associated COPD has not yet been established. We measured absolute telomere length (aTL) in peripheral leukocytes from 231 HIV-infected adults. Comparisons were made to 691 HIV-uninfected individuals from a population-based sample. Subject quartiles of aTL were assessed for relationships with measures of HIV disease severity, airflow obstruction, and emphysema severity on computed tomographic (CT) imaging. Multivariable regression models identified factors associated with shortened aTL. Compared to HIV-uninfected subjects, the mean aTL in HIV-infected patients was markedly shorter by 27 kbp/genome (p<0.001); however, the slopes of aTL vs. age were not different (p=0.469). Patients with longer known durations of HIV infection (p=0.019) and lower nadir CD4 cell counts (p=0.023) had shorter aTL. Shorter aTL were also associated with older age (p=0.026), smoking (p=0.005), reduced forced expiratory volume in one second (p=0.030), and worse CT emphysema severity score (p=0.049). HIV-infected subjects demonstrate advanced cellular aging, yet in a cART-treated cohort, the relationship between aTL and age appears no different from that of HIV-uninfected subjects.


Journal of Applied Physiology | 2011

Endotoxin-induced cardiovascular dysfunction in mice: effect of simvastatin

Koichi Suda; Jihyoun Eom; Jen Erh Jaw; Tammy Mui; Ni Bai; Chris Or; David A. Ngan; Yuexin Li; Xi Wang; Masashi Tsuruta; Sheena Tam; S. Paul Man; Stephan F. van Eeden; Don D. Sin

Lung infections are associated with acute lung injury (ALI), systemic inflammation, and vascular events. Clinical studies suggest that statins improve health outcomes of patients with pneumonia and ALI. The mechanisms by which this occurs are unknown. The aim of this study was to determine whether statins attenuate systemic inflammation and cardiovascular dysfunction related to ALI in mice. Simvastatin (SS; 20 mg/kg) or vehicle solution was instilled intraperitoneally into mice 24 h before and again just prior to intratracheal LPS instillation (1 μg/g). These mice were then anesthetized with 2.0% isoflurane and underwent a short surgical procedure to instill LPS. Four hours later, IL-6 levels in bronchoalveolar lavage fluid and in arterial and venous serum were measured. Cardiac function was evaluated using 2-D echocardiography, and endothelial function was determined using wire myography on aortic sections. LPS induced a significant increase in serum IL-6 levels. SS reduced venous (P = 0.040) but not arterial concentrations of IL-6 (P = 0.112). SS improved the maximal vasodilatory response of the aorta to ACh (P = 0.004) but not to sodium nitroprusside (P = 1.000). SS also improved cardiac output (P = 0.023). Vasodilatory response to ACh was impaired when aorta from untreated mice was incubated with ex vivo IL-6 (P = 0.004), whereas in the aorta from mice pretreated with SS, the vasodilatory response did not change with IL-6 incubation (P = 0.387). SS significantly improved LPS-induced cardiovascular dysfunction possibly by reducing systemic expression of IL-6 and its downstream signaling pathways. These findings may explain how statins improve health outcomes in patients with ALI.


European Respiratory Journal | 2016

Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation

Jen Erh Jaw; Masashi Tsuruta; Yeni Oh; John Schipilow; Yuki Hirano; David A. Ngan; Koichi Suda; Yuexin Li; Jin Young Oh; Konosuke Moritani; Sheena Tam; Nancy L. Ford; Stephan F. van Eeden; Joanne L. Wright; S. F. Paul Man; Don D. Sin

Epidemiological studies have implicated lung inflammation as a risk factor for acute cardiovascular events, but the underlying mechanisms linking lung injury with cardiovascular events are largely unknown. Our objective was to develop a novel murine model of acute atheromatous plaque rupture related to lung inflammation and to investigate the role of neutrophils in this process. Lipopolysaccharide (LPS; 3 mg·kg−1) or saline (control) was instilled directly into the lungs of male apolipoprotein E-null C57BL/6J mice following 8 weeks of a Western-type diet. 24 h later, atheromas in the right brachiocephalic trunk were assessed for stability ex vivo using high-resolution optical projection tomography and histology. 68% of LPS-exposed mice developed vulnerable plaques, characterised by intraplaque haemorrhage and thrombus, versus 12% of saline-exposed mice (p=0.0004). Plaque instability was detectable as early as 8 h post-intratracheal LPS instillation, but not with intraperitoneal instillation. Depletion of circulating neutrophils attenuated plaque rupture. We have established a novel plaque rupture model related to lung injury induced by intratracheal exposure to LPS. In this model, neutrophils play an important role in both lung inflammation and plaque rupture. This model could be useful for screening therapeutic targets to prevent acute vascular events related to lung inflammation. Neutrophils play an important role in atherosclerotic plaque vulnerability related to LPS-induced lung inflammation http://ow.ly/Y7dWW


Thorax | 2015

The relationship between Helicobacter pylori seropositivity and COPD

Marc A. Sze; Yu Wei Roy Chen; Sheena Tam; Donald P. Tashkin; Robert A. Wise; John E. Connett; S. F. Paul Man; Don D. Sin

Rationale Chronic systemic infections such as those with Helicobacter pylori (H. pylori) may contribute to the evolution and progression of chronic obstructive pulmonary disease (COPD). Using data from the Lung Health Study (LHS), we determined the relationship of H. pylori infection with the severity and progression of COPD. Methods Using an immunoassay, we measured H. pylori immunoglobulin G (IgG) antibody titres in serum samples of 4765 patients with mild-to-moderate COPD. We then determined their relationship with the individuals FEV1 and the rate of decline in FEV1 and mortality over 11 years using multiple regression analysis. Results Approximately 18% of the patients were seropositive to H. pylori and these individuals demonstrated lower FEV1 (L) values at every study visit compared with individuals who were seronegative for H. pylori (p value=0.00012). However, patients with seropositivity to H. pylori were on average 0.012 m shorter than those with seronegativity (p value=0.0015). The significant relationship between FEV1 and H. pylori seropositivity disappeared when FEV1 per cent predicted (FEV1pp) was used (p value=0.45). H. pylori seropositive individuals had greater circulating C reactive protein (CRP) levels compared with H. pylori seronegative individuals (p value=0.012), and had increased risk of cardiovascular mortality (relative risk 1.61, p=0.05). Conclusions H. pylori infection was associated with reduced lung function that is most likely due to the effect of the bacterium on lung growth earlier in life. It is also associated with systemic inflammation and increased risk of cardiovascular mortality in patients with COPD. Trial registration numbers NCT00000568 and NCT00000569.


Clinical & Experimental Allergy | 2016

Effect of controlled human exposure to diesel exhaust and allergen on airway surfactant protein D, myeloperoxidase and club (Clara) cell secretory protein 16.

Bradly J. Biagioni; Sheena Tam; Yu‐Wei Roy Chen; Don D. Sin; Chris Carlsten

Air pollution is a major cause of global morbidity and mortality. Air pollution and aeroallergens aggravate respiratory illness, but the variable effects of air pollutants and allergens in the lung are poorly understood.


Cardiovascular Research | 2017

Surfactant protein-D deficiency suppresses systemic inflammation and reduces atherosclerosis in ApoE knockout mice

Yuki Hirano; Alex GoEun Choi; Masashi Tsuruta; Jen Erh Jaw; Yeni Oh; David A. Ngan; Konosuke Moritani; Yu Wei Roy Chen; Sheena Tam; Yuexin Li; Dragoş M. Vasilescu; James C. Hogg; Gordon A. Francis; Pascal Bernatchez; S. F. Man; Don D. Sin

Aims Although surfactant protein-D (SP-D) is a pneumoprotein that is predominantly synthesized by type II epithelial cells in the lung, individuals with increased circulating levels of SP-D are at an elevated risk of mortality from ischemic heart disease. Whether SP-D contributes directly to atherosclerosis is unknown. We determined the effects of SP-D gene deletion in a mouse model of atherosclerosis. Methods and results SP-D knockout (KO) mice were crossed with hyperlipidemic and atherosclerosis-prone apolipoprotein E (ApoE) KO mice to generate SP-D/ApoE double knockout (DKO) mice. Mice were placed on a high-fat diet for 12 weeks beginning at 8 weeks of age. Compared with ApoE KO mice, SP-D/ApoE DKO mice had significantly less atherosclerosis with reduced macrophage accumulation, decreased local macrophage proliferation, and increased smooth muscle cell coverage in plaques. Interestingly, SP-D deficiency worsened hypercholesterolemia and induced obesity and insulin resistance but suppressed plasma interleukin-6 (IL-6) levels. SP-D deficiency also reduced blood monocytes and neutrophils counts in ApoE KO mice. Conclusion SP-D deficiency reduces atherosclerosis in part by decreasing the accumulation and proliferation of macrophages and by reducing IL-6 levels systemically. SP-D is a promising therapeutic target for cachectic COPD patients with elevated circulating SP-D levels who are at increased risk of cardiovascular morbidity and mortality.


Chest | 2018

Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD

Minhee Jin; Eun Chong Lee; Seung Won Ra; Nick Fishbane; Sheena Tam; Gerard J. Criner; Prescott G. Woodruff; Stephen C. Lazarus; Richard K. Albert; John E. Connett; MeiLan K. Han; Fernando J. Martinez; Shawn D. Aaron; Robert M. Reed; S. F. Paul Man; Janice M. Leung; Don D. Sin

Background COPD is an age‐related disease. The role of cellular senescence in COPD has not been fully elucidated. This study examined the relationship between telomere length of peripheral blood leukocytes and clinical outcomes, including health status, rate of exacerbations, and risk of mortality in individuals with COPD. Methods Using quantitative polymerase chain reaction, we measured the absolute telomere length (aTL) of DNA extracted from blood samples of 576 participants with moderate‐to‐severe COPD treated with either azithromycin or placebo for 12 months in the Macrolide Azithromycin for Prevention of Exacerbations of COPD (MACRO) study. All participants were followed for approximately 13 months, during which time health status and exacerbations were carefully ascertained, and an additional 29 months for mortality. The rates of exacerbation and mortality were determined by dividing the aTL into two groups using the median value as the cutoff. Results Participants with shorter telomere length had worse health status defined by higher St. George’s Respiratory Questionnaire scores (&bgr; = −0.09, P = .034). In the placebo arm of the study, the rate of exacerbation (rate ratio, 1.50; 95% CI, 1.16‐1.95; P = .002) and the risk of mortality (hazard ratio, 9.45; 95% CI, 2.85‐31.36; P = .015) were significantly higher in the shorter telomere group than in the longer telomere group; these differences were not observed in the azithromycin arm (interaction P = .008 for exacerbation and interaction P = .017 for mortality) Conclusions These data suggest that replicative senescence may help to predict poor outcomes in COPD. Shorter leukocyte telomere lengths may represent a clinically translatable biomarker for identifying individuals at increased risk of poor clinical outcomes in COPD.


American Journal of Respiratory and Critical Care Medicine | 2013

Club cell protein 16 and disease progression in chronic obstructive pulmonary disease.

Hye Yun Park; Andrew Churg; Joanne L. Wright; Yuexin Li; Sheena Tam; S. F. Paul Man; Donald P. Tashkin; Robert A. Wise; John E. Connett; Don D. Sin


Respiratory Research | 2017

Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori

Seung Won Ra; Marc A. Sze; Eun Chong Lee; Sheena Tam; Yeni Oh; Nick Fishbane; Gerard J. Criner; Prescott G. Woodruff; Stephen C. Lazarus; Richard K. Albert; John E. Connett; MeiLan K. Han; Fernando J. Martinez; Shawn D. Aaron; Robert M. Reed; S. F. Paul Man; Don D. Sin

Collaboration


Dive into the Sheena Tam's collaboration.

Top Co-Authors

Avatar

Don D. Sin

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Yuexin Li

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Masashi Tsuruta

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Yeni Oh

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

S. F. Paul Man

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

David A. Ngan

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Jen Erh Jaw

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Koichi Suda

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Joanne L. Wright

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Stephan F. van Eeden

University of British Columbia

View shared research outputs
Researchain Logo
Decentralizing Knowledge